TearSolutions just landed two FDA designations for Lacripep, a first-in-class synthetic peptide aimed at neurotrophic keratitis. The agency granted both Rare Pediatric Disease and Fast Track status. A Phase 2 trial evaluating safety and efficacy in fifty-four patients has already dosed its first participants.
Neurotrophic keratitis, or NK, is a rare degenerative condition. The corneal nerves stop working. The eye loses its ability to sense damage. The cornea breaks down. There are very few treatment options. A peptide that could reverse the underlying nerve damage would change the standard of care entirely.
What Lacripep Is and How It Works
Lacripep is a synthetic peptide derived from lacritin. Lacritin is a natural tear protein that the eye produces to maintain corneal health. In preclinical work, the peptide did three things. It resolved underlying nerve damage. It reactivated physiological basal tear secretion. And it restored health to the corneal epithelium. Those three effects address the root cause of NK, not just the surface symptoms.
Here’s why this matters. Current NK treatments focus on lubricating the eye surface or closing the tear ducts to retain moisture. They do not repair the nerves. A therapy that actually restores corneal innervation would be the first disease-modifying option for these patients.
The Regulatory Path Forward
The Rare Pediatric Disease designation comes with a voucher. If Lacripep is approved, TearSolutions receives a priority review voucher that it can sell or use for another drug. Those vouchers have traded for over one hundred million dollars in past deals. Fast Track means more frequent meetings with the FDA and eligibility for rolling review and accelerated approval.
These two designations together signal that the FDA sees genuine unmet need in NK. The agency does not hand out both designations lightly. It reserves them for diseases where the current standard of care is genuinely inadequate. That’s exactly the situation with neurotrophic keratitis.
Expert Insight
But what most people miss is the formulation challenge. Eye-drop peptides face a brutal pharmacokinetic problem. The tear film clears the ocular surface within minutes. A peptide has maybe sixty to ninety seconds to penetrate the cornea before it gets washed down the nasolacrimal duct. Most peptide teams underestimate how different ocular delivery is from subcutaneous injection. The peptide that works beautifully in a dish often never reaches the corneal nerves in a patient.
TearSolutions has been working on this for years. The fact that they moved into Phase 2 suggests they solved the residence-time problem. But the real test is whether the Phase 2 efficacy data holds up in a larger population. Neurotrophic keratitis has several subtypes. What works for post-herpetic NK may not work for diabetic NK. Experienced teams know to stratify their patients carefully.
So what does this mean for the broader peptide field? The natural question is whether lacritin-derived peptides could work for other ocular surface diseases. Dry eye disease affects millions of people. If Lacripep proves that a synthetic tear protein peptide can restore corneal health in NK, the same approach could be adapted for moderate to severe dry eye. That’s a much larger market. But the formulation hurdles scale non-linearly with target tissue depth.
Another question readers ask is about the timeline. Fast Track does not mean fast approval. It means faster communication with regulators. A Phase 2 trial in fifty-four patients is designed to find a signal. If the signal is strong, a Phase 3 pivotal trial follows. Realistically, an NDA filing is three to four years away at minimum. But for a rare disease with no disease-modifying therapies, the bar for approval may be lower than for a crowded indication like dry eye.
Further Reading
- Cenna Nubytide Peptide Takes Aim at Amyloid Production in Alzheimer’s
- FDA Moves to Reclassify 12 Peptides in Major Regulatory Shift
- Retatrutide Hits 30% Weight Loss in Pivotal Phase 3 Trial
Last reviewed: June 2026. Peptide Proof Editorial Team. Sources: EyeWorld Weekly, June 5, 2026
